XML 39 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Statements of Operations (Unaudited) (USD $)
 3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Revenues:        
License fee and milestone revenue $ 8,388,760 $ 22,495 $ 8,417,330 $ 68,240
License fee and milestone revenue from affiliated entity 106,250 106,250 318,750 318,750
Revenue under collaborative research and development arrangements with affiliated entity   116,234 0 116,234
Grants and miscellaneous revenue 991,835 609,717 2,991,600 2,480,675
Total revenues 9,486,845 854,696 11,727,680 2,983,899
Operating expenses:        
Research and development 5,438,405 4,972,319 14,964,599 13,541,984
General and administrative 3,282,796 2,674,362 9,303,535 7,859,359
Gain on sale of assets 0 (500,000) (1,000,000) (1,151,000)
Total operating expenses 8,721,201 7,146,681 23,268,134 20,250,343
Income (Loss) from operations 765,644 (6,291,985) (11,540,454) (17,266,444)
Other income (expense):        
Interest and other income, net 46,787 37,013 123,638 109,593
Change in fair value of common stock warrants (34,952,210) (1,113,638) (39,579,704) (1,067,029)
Gain (Loss) on investment in affiliated entity 3,248,926 736,121 380,791 (817,796)
Net loss (30,890,853) (6,632,489) (50,615,729) (19,041,676)
Net loss attributable to non-controlling interest 13,443 10,413 41,611 31,472
Net loss attributable to Inovio Pharmaceuticals, Inc. $ (30,877,410) $ (6,622,076) $ (50,574,118) $ (19,010,204)
Loss per common share—basic and diluted:        
Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders (in USD per share) $ (0.16) $ (0.05) $ (0.29) $ (0.14)
Weighted average number of common shares outstanding—basic and diluted 191,956,155 135,389,308 176,183,075 135,108,699